MAPT and supranuclear palsy, progressive, 1: We employed two tauopathy cell models to assess the activity of QC-01–175 in human neurons, one derived from a PSP patient carrier of the tau-A152T risk variant, and one derived from a behavioral-variant FTD patient carrier of the tau-P301L autosomal dominant mutation (both heterozygous, Figure 2—source data 1) (Seo et al., 2017; Silva et al., 2016; Coppola et al., 2012; Mirra et al., 1999).